Lantern Pharma Inc. has announced additional results from its completed Phase 1a dose-escalation clinical trial of LP-184, a biomarker-activated cancer drug candidate. The trial enrolled 63 heavily pre-treated patients with advanced solid tumors, many of whom had DNA damage repair pathway deficiencies. The study met all primary endpoints for safety and tolerability, and established a recommended Phase 2 dose. At or above therapeutic dose levels, LP-184 demonstrated a 54% disease control rate, showing encouraging efficacy signals in DNA damage repair-deficient cancers. Results from the Phase 1a study were presented in a recent company webinar, which included detailed clinical data, patient case studies, and future development plans. Lantern Pharma is advancing multiple biomarker-guided Phase 1b/2 clinical trials in indications such as triple-negative breast cancer, glioblastoma multiforme, non-small cell lung cancer, and advanced urothelial carcinoma.